Twin Lakes Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Twin Lakes Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$122K	Sell	158 -107	-40%	-$81.9K	0.06%	99
2025 Q4	$205K	Hold	265	–	–	0.09%	84
2025 Q3	$149K	Sell	265 -2	-0.7%	-$1.13K	0.07%	92
2025 Q2	$140K	Buy	267 +1	+0.4%	+$558	0.09%	88
2025 Q1	$169K	Hold	266	–	–	0.11%	86
2024 Q4	$189K	Hold	266	–	–	0.12%	87
2024 Q3	$280K	Hold	266	–	–	0.18%	73
2024 Q2	$280K	Hold	266	–	–	0.19%	69
2024 Q1	$256K	Hold	266	–	–	0.17%	74
2023 Q4	$234K	Hold	266	–	–	0.16%	77
2023 Q3	$219K	Hold	266	–	–	0.16%	74
2023 Q2	$191K	Sell	266 -25	-9%	-$19.3K	0.14%	84
2023 Q1	$239K	Hold	291	–	–	0.18%	74
2022 Q4	$210K	Hold	291	–	–	0.16%	77
2022 Q3	$200K	Hold	291	–	–	0.16%	83
2022 Q2	$172K	Hold	291	–	–	0.12%	74
2022 Q1	$203K	Buy	291 +15	+5%	+$9.49K	0.11%	93
2021 Q4	$174K	Sell	276 -14	-5%	-$8.61K	0.09%	105
2021 Q3	$176K	Sell	290 -37	-11%	-$23K	0.1%	96
2021 Q2	$183K	Sell	327 -67	-17%	-$33.9K	0.1%	86
2021 Q1	$186K	Buy	+394	New	+$192K	0.11%	81

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Twin Lakes Capital Management's REGN Position: Q1 2026 in Review

Twin Lakes Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 40% in Q1 2026, selling an estimated $81.9K and leaving 158 shares worth $122K. The position accounts for 0.06% of the portfolio, ranked #99.

Twin Lakes Capital Management first reported a position in REGN in Q1 2021 and has held it in 21 quarters since. The position peaked at $280K in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Twin Lakes Capital Management held 158 shares of Regeneron Pharmaceuticals worth $122K as of Q1 2026.
Twin Lakes Capital Management sold 107 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $81.9K.
Regeneron Pharmaceuticals made up 0.06% of Twin Lakes Capital Management's portfolio in Q1 2026, its #99 holding.
Twin Lakes Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
Twin Lakes Capital Management's Regeneron Pharmaceuticals position peaked at $280K in Q3 2024.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Twin Lakes Capital Management's 13F filing for Q1 2026, filed 18 May 2026.